Art

J-GLOBAL ID：201902239475368395   Reference number：19A0043392

Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients

慢性骨髄性白血病患者におけるCD57陽性ヘルパー/細胞傷害性CD4T細胞の新たなサブセットによるダサチニブ誘導抗白血病細胞性免疫

Author (10)： WATANABE Naoki (Juntendo Univ. School of Medicine, Tokyo, JPN) ,  TAKAKU Tomoiku (Juntendo Univ. School of Medicine, Tokyo, JPN) ,  TAKEDA Kazuyoshi (Juntendo Univ., Tokyo, JPN) ,  SHIRANE Shuichi (Juntendo Univ. School of Medicine, Tokyo, JPN) ,  TOYOTA Tokuko (Juntendo Univ. School of Medicine, Tokyo, JPN) ,  KOIKE Michiaki (Juntendo Shizuoka Hospital, Shizuoka, JPN) ,  NOGUCHI Masaaki (Juntendo Urayasu Hospital, Chiba, JPN) ,  HIRANO Takao (Juntendo Nerima Hospital, Tokyo, JPN) ,  FUJIWARA Hiroshi (Ehime Univ., Ehime, JPN) ,  KOMATSU Norio (Juntendo Univ. School of Medicine, Tokyo, JPN)
Material： International Journal of Hematology  (Int J Hematol)
Volume： 108  Issue： 6  Page： 588-597  Publication year： Dec. 2018 
JST Material Number： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： *antitumor drug ,...
Semi thesaurus term： *CD4 T cell ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0043392&from=J-GLOBAL&jstjournalNo=F0888A") }}

JST classification (3)： Blood cell tumors(=neoplasms)  (GK04000M) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (1)： Dasatinib

Reference (37)：

• Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872-84.
• Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917-27.
• Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 2007;29:2289-308.
• Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044-54.
• Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333-40.

Terms in the title (11)： 慢性骨髄性白血病 ,  患者 ,  CD57 ,  ヘルパー ,  細胞傷害性 ,  CD4T細胞 ,  サブセット ,  ダサチニブ ,  誘導 ,  白血病 ,  細胞性免疫